

**Mrs. Zehra Oksuz Karaarslan**  
Mersin University Medical  
Pharmaceutical Microbiology department, Faculty of Pharmacy  
No:31, Çiftlikköy, Vali Şenol Engin Cd.  
33110 Mersin  
Turkey

**med update europe GmbH**

Hagenauer Straße 53  
65203 Wiesbaden  
Tel.: + 49 611 9458799 - 1  
Fax: + 49 611 9458799 - 9  
info@medupdate-europe.com  
[www.medupdate-europe.com](http://www.medupdate-europe.com)  
Ust-IdNr. DE287642984  
Nassauische Sparkasse  
IBAN DE33 5105 0015 0173 0358 41  
BIC NASSDE55XXX  
Managing Director: Claudia Weidenfeller  
Jurisdiction: Wiesbaden, HRB 26814

Wiesbaden, May 11<sup>th</sup> 2016

## Acceptance of ePoster

Dear Mrs Oksuz Karaarslan,

Thank you for attending the 3<sup>rd</sup> Gastro Update Europe which took place April 29-30, 2016 in Prague, Czech Republic.

We are happy to confirm that your submitted ePoster "Prognostic values of serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma" was accepted by the Scientific Board of the congress and displayed on-site.

During the congress all important fields of gastroenterology were covered in two intense and exciting days. Both clinicians and practitioners profited immensely from the lectures, and improved their clinical and practical knowledge as well as the quality of their daily work. Participants also had the opportunity to interact with colleagues, exchange experiences and information on current trends and future directions in gastroenterology.

We hope to welcome you to the 4<sup>th</sup> Gastro Update Europe in Vienna, 7-8 April, 2017.

Sincerely,



Claudia Weidenfeller  
Managing Director  
med update europe GmbH

med update europe GmbH  
Hagenauer Straße 53  
65203 Wiesbaden  
Tel.: 06 11 / 94 58 799 0  
Fax: 06 11 / 94 58 799 9

**Prognostic values of serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma**

**ÖKSÜZ Z<sup>1</sup>, SERİN MS<sup>1,2</sup>, KAPLAN E<sup>2</sup>, DÖĞEN A<sup>1</sup>, TEZCAN S<sup>3</sup>, ASLAN G<sup>3</sup>, EMEKDAŞ G<sup>3</sup>, SEZGİN O<sup>4</sup>, ALTINTAŞ E<sup>4</sup>, TİFTİK EN<sup>5</sup>, BAHARODİ A<sup>6</sup>**

<sup>1</sup>Mersin University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Mersin, TURKEY

<sup>2</sup>Mersin University, Advanced Technology Applications Research and Training Center, Mersin, TURKEY

<sup>3</sup>Mersin University, Faculty of medicine, Department of Medical Microbiology, Mersin, TURKEY

<sup>4</sup>Mersin University, Faculty of medicine, Department of Gastroenterology, Mersin, TURKEY

<sup>5</sup>Mersin University, Faculty of medicine, Department of Hematology, Mersin, Turkey

<sup>6</sup>Çukurova University, Faculty of medicine, Department of Medical Microbiology, Adana, TURKEY

Hepatitis C virus (HCV) infection is a serious global health problem in the worldwide. MicroRNAs (miRNAs), 17- to 25-nucleotide noncoding RNAs that are frequently dysregulated in hepatocellular carcinoma (HCC). In this study, plasma samples of patients with chronic hepatitis C (CHC), cirrhosis and HCC examined for a total of 60 miRNA expression profiles to provide potentially important noninvasive biomarkers to be used for early diagnosis of HCC.

The study was conducted with 26 samples of CHC patients, 30 samples of 30 cirrhosis patients, 8 samples of HCC patients and 30 samples of healthy controls. Expression profiles of 60 miRNA were investigated with high capacity qRT-PCR by using 96.96 dynamic array IFCs.

The examples studied by Quantitative Real-Time PCR was evaluated by Biogazelle qBase PLUS statistical analysis. The expression profiles of 60 miRNA were analyzed in patient's plasma of CHC, cirrhosis and HCC and compared with control group samples. CHC group the expression levels of miR-30a-5p, miR-30c-5p, miR-206 and miR-302c-3p were found statistically significant ( $p < 0.05$ ). Cirrhosis group; the expression levels of miR-30c-5p, miR-223-3p, miR-302c-3p, miR-17-5p, miR-130a-3p, miR-93-5p and miR-302c-5p were found statistically significant ( $p < 0.05$ ). HCC group; the expression levels of miR-17-5p, miR-223-3p and miR-24-3p were found statistically significant ( $p < 0.05$ ).

When expression levels of 60 miRNA were compared between 3 patients group and control groups, miR-223-3p, miR-17-5p and miR-24-3p were found to be potentially important non-invasive biomarkers for early detection of HCC. These three miRNAs should be studied in further and larger volume of patient populations in cirrhosis and HCC in the future.

**Keywords: Hepatitis C virus, cirrhosis, hepatocellular carcinoma, miRNA, Reverse Transcription Polymerase Chain Reaction (RT-PCR)**